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recurrent	 or	 hormone-sensitive	metastatic	 prostate	 cancer,	 which	 has	 energised	 the	 UK	 prostate	
cancer	 oncology	 community.	 Achieving	 rapid	 recruitment,	 it	 has	 generated	 results	 that	 have	
changed	 systemic	 therapy	 practice:	 Docetaxel	 has	 been	 added	 to	 lifelong	 androgen	 deprivation	
therapy	as	the	standard	of	care	(SoC)	in	this	population,	having	demonstrated	a	clinically	significant	
survival	 advantage	 [1],	 and	 abiraterone	 is	 currently	 being	 evaluated	 by	 NICE	 after	 showing	 a	
comparable	survival	benefit	[2,3].	












progression	 or	 death	 from	 prostate	 cancer.	 Secondary	 outcomes	 were	 symptomatic	 local	 events,	
progression-free	 survival	 (PFS)	 equivalent	 to	 FFS	 but	 ignoring	 biochemical	 events,	 and	metastatic	
progression-free	 survival	 (MPFS)	 defined	 as	 time	 to	 new	 metastases,	 progression	 of	 existing	
metastases	or	death.	
The	target	sample	size	was	1250	patients,	selected	on	the	assumption	of	1	and	3.5	year	median	FFS	
and	OS	 respectively	 for	 the	SoC	control	 group,	and	25%	 relative	 improvement	 in	hazard	 ratios	 for	
failure	and	death	for	patients	receiving	SoC+RT.	It	was	observed	during	recruitment	that	the	two	RT	
schedules	were	 being	 used	 roughly	 equally,	 and	 therefore	 the	 sample	 size	was	 increased	 to	 1800	
patients,	 to	 provide	 power	 to	 detect	 differences	 in	 FFS	 for	 each	 RT	 schedule-defined	 subgroup	
versus	SoC	alone.	
Based	 on	 accumulating	 external	 results,	 and	 without	 reference	 to	 data	 from	 STAMPEDE,	
investigators	 concluded	 in	May	 2018	 that	 any	 benefit	 from	 RT	would	 be	 greater	 in	 patients	with	
lower	metastatic	burden,	and	that	this	potential	benefit	could	be	tested	with	reasonable	power	 in	
the	subgroup	of	STAMPEDE	patients	with	lower	burden.	
Survival	 analysis	 used	 Cox	 proportional	 hazards	 and	 flexible	 parametric	 models,	 adjusted	 for	
stratification	 factors.	 For	 the	 subgroup	 analysis	 that	 tested	 the	 effects	 of	 prostate	 RT	 by	 baseline	





cancer	 were	 randomised	 from	 117	 sites,	 1029	 to	 SoC	 and	 1032	 to	 SoC+RT.	 The	 arms	 were	 well	
balanced	 with	 40%	 and	 54%	 of	 patients	 having	 lower	 and	 higher	 metastatic	 disease	 burden	
respectively,	and	6%	having	unknown	burden.	Of	the	patients	allocated	to	SoC+RT	88%	received	one	
of	the	protocol	RT	schedules,	6%	an	alternative	schedule,	and	6%	declined	treatment.	
Across	 the	whole	patient	group	a	 significant	 improvement	was	 seen	 in	FFS	 (HR	0.76;	95%	CI	0.68-









did	 not	 find	 a	 significant	 improvement	 in	 OS	 for	 SoC+RT	 in	 the	 whole	 patient	 group	 studied.	
However,	a	significant	OS	benefit	was	seen	for	patients	with	lower	metastatic	burden	treated	using	
SoC+RT	 (p=.007)	 in	 a	 subgroup	 analysis	 that	met	 credibility	 criteria	 proposed	 by	 Sun	 et	 al	 [7].	 An	
interaction	test	indicates	that	the	observed	effect	was	independent	of	other	variables	assessed.	The	
HORRAD	 study	 of	 432	 men	 with	 metastatic	 prostate	 cancer	 randomised	 to	 receive	 androgen	
deprivation	therapy	(ADT)	alone	or	with	RT	recently	reported	no	significant	 improvement	in	OS	for	
the	ADT+RT	arm	when	assessed	across	all	patients,	but	a	 trend	 for	 improved	OS	 in	 those	patients	
with	 lower	metastatic	 disease	burden	 treated	using	ADT+RT	 (p=.063)	 [8].	 This	 trend	 for	 improved	
survival	 in	patients	with	lower	metastatic	burden	receiving	SoC+RT	has	now	been	confirmed	in	the	
larger	STAMPEDE	study.		
STAMPEDE	 recruited	 rapidly,	 and	 consequently	median	 follow-up	 (37	months)	 is	 currently	 shorter	
than	median	survival	 (46	months).	Longer-term	analysis	of	STAMPEDE	data	may	provide	additional	
insights	 for	 population	 subsets.	 Palliative	 chemotherapy	 with	 docetaxel	 has	 become	 SoC	 for	
hormone-sensitive	 metastatic	 prostate	 cancer,	 with	 a	 survival	 benefit	 comparable	 to	 abiraterone	
therapy	until	disease	progression.	Patients	receiving	docetaxel	in	this	study	had	the	shortest	follow-
up,	and	although	no	significant	difference	in	OS	or	FFS	was	seen	for	these	patients,	this	may	change	
with	 longer	 follow-up.	 Improved	 systemic	 therapy,	 providing	 better	 control	 of	 metastases,	 may	




the	a/b	 ratio	 for	 prostate	 cancer	was	 relatively	 low	 [10],	 RT	 schedules	 of	 55Gy/20#/26	 days	 and	
36/6#/36	days	were	chosen	for	the	trial.	STAMPEDE	has	shown	some	evidence	of	heterogeneity	 in	
FFS	by	RT	schedule	(p=0.072):	while	a	clear	FFS	benefit	was	seen	for	SoC+55Gy/20#	compared	to	SoC	
alone	 (HR	0.69;	95%	CI	0.59-0.8;	p	<	10-6),	 for	 SoC+36Gy/6#	 the	benefit	did	not	 reach	 significance	
(HR=0.85;	95%	CI	0.73-0.99;	p	=	0.033).	Longer-term	analysis	may	shed	more	light	on	any	difference	
in	 the	 effectiveness	 of	 the	 two	 RT	 schedules,	 potentially	 guiding	 identification	 of	 an	 optimised	
schedule,	which	future	translational	research	might	allow	to	be	personalised.	
Summary	
In	 newly-diagnosed	 patients	 with	 prostate	 cancer	 and	 low-burden	 metastatic	 disease,	 OS	 was	
improved	 by	 adding	 prostate	 RT	 to	 SoC,	 and	 consequently	 SoC+RT	 should	 be	 considered	 the	 new	
standard	of	care	for	this	population.	The	STAMPEDE	authors	suggest	that	RT	might	be	given	as	60	Gy	




Figure	 1.	 Kaplan-Meier	 curves	 and	 fitted	 survival	 models	 for	 STAMPEDE	 Arm	 K	 patients	 having	 lower	 and	
higher	 metastatic	 disease	 burdens	 (from	 Figure	 4	 of	 Parker	 et	 al	 [5]	 https://doi.org/10.1016/S0140-
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